Meeting
2018 ASCO Annual Meeting
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
Authors
Damien Pouessel
Saint Louis Hospital, Paris, France
Damien Pouessel , Augustin Mervoyer , Delphine Larrieu-Ciron , Bastien Cabarrou , Justine Attal , Marie Robert , Jean-Sebastien Frenel , Pascale Olivier , Muriel Poublanc , Muriel Mounier , Elizabeth Moyal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02866747
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2046)
DOI
10.1200/JCO.2018.36.15_suppl.2046
Abstract #
2046
Poster Bd #
204
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
First Author: Eliza Anne Hawkes
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon
Poster
2019 ASCO Annual Meeting
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.
First Author: Michael Lim
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang